Barr Labs to start selling anti-nausea drug
-
- January
- 2
Barr Laboratories Inc., the Pomona-based generic-drug unit of Barr Pharmaceuticals Inc., has received regulatory approval to begin selling a generic version of Kytril, a brand-name drug used to treat nausea and vomiting associated with cancer treatments.
Barr said it received final approval from the Food and Drug Administration following the expiration of the drug’s patent Friday.
Kytril, manufactured by Roche Laboratories Inc., had annual sales of $88 million ending October, based on industry data.
Barr plans to launch its generic product shortly, it said.
This entry was posted
on Wednesday, January 2nd, 2008 at 5:59 pm by David Schepp.
You can follow any responses to this entry through the RSS 2.0 feed.
Category: Consumer, Health care, New products
Print
| 
Email
